AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02951611 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation
Study NCT04649528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effective endurance 4x4 training - Supervised
Description: Exercise intervention utilizing 4x4min aerobic high-intensity interval training
Study NCT04649528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effective endurance 4x4 training - APP
Description: Exercise intervention utilizing 4x4min aerobic high-intensity interval training
Study NCT04228978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Walking exercise combined with weight loss
Study NCT04228978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Walking exercise
Study NCT04228978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking exercise
Study NCT02462486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar Pegol
Description: Abicipar pegol intravitreal injection.
Study NCT02462486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab intravitreal injection.
Study NCT02462486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Sham injection.
Study NCT00220727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Description: IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
Study NCT02809768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Study NCT02809768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Study NCT02809768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study NCT02809768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Study NCT02111434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone 250 mg injection per 3-4 weeks for 6 months
Study NCT01999894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine HCl
Description: Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
Study NCT00006228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT03214315 — intervention group
Intervention type: PROCEDURE
Intervention: Visceral adipose tissue specimen
Description: specimen
Study NCT03047655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention (physical activity)
Description: Dietary treatment with or without additional motivation on more physical activity
Study NCT03047655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention (PUFA/isomaltulose-enriched muffin)
Study NCT02825667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy sessions
Description: Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
Study NCT04280588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
Study NCT03960944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 30 Min Yoga session included of Physical posture, Breathing exercise, Yoga games and Relaxation.
Study NCT04102566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
Study NCT04102566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: We'll be adding education to patient's post-operative instructions to aid in their pain control management.
Study NCT00279695 — intervention group
Intervention type: PROCEDURE
Intervention: high frequency ultrasound examination
Description: high frequency ultrasound examination of the eye
Study NCT02038647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib tablets
Study NCT02038647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching tablets
Study NCT02038647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous injection
Study NCT02038647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel intravenous injection
Study NCT03510689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: Resting echocardiograms (Vivid E9 or E95, GE Healthcare) with conventional measures of systolic and diastolic function, in conjunction with posthoc quantitation of novel measures of strain and strain rate will be obtained at each study time point.
Study NCT03510689 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing
Description: A cardiopulmonary exercise test (CPET, also called V02 test) will be completed at each study time point utilizing a standard clinical protocol, on either a stationary bike or treadmill. The purpose of this test is to estimate maximal oxygen consumption (V02 max) as in index of cardiopulmonary fitness. Resting ECG, heart rate, and BP will be obtained prior to beginning the test, during each stage of the test and for 5 minutes after the test is stopped.
Study NCT03510689 — intervention group
Intervention type: OTHER
Intervention: Blood Collection
Description: We will obtain blood samples (approximately 16mL) at baseline and (approximately 12mL) at each follow-up visit. Typically these will be drawn via peripheral venipuncture, however if patients have a port-a-cath in place, blood may be drawn from the port instead.
Study NCT05931822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silver Diamine Fluoride 38%
Description: silver diamine fluoride 38% brushed on the cavity for 1 minute before adding high viscosity glass ionomer restoration in one molar
Study NCT05931822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish
Description: fluoride varnish brushed after adding the high viscosity glass ionomer restoration in the contralateral molar
Study NCT00834782 — intervention group
Intervention type: PROCEDURE
Intervention: IOP measurement
Description: Measuring IOP
Study NCT00593619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron dextran
Description: 300mg in 250cc normal saline given over 2 hours
Study NCT00593619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: 300mg in 250cc normal saline given over 2 hours
Study NCT04576559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified dental visual aids
Description: Modified Dental visual aids in the form of pictures created by the main investigator
Study NCT04576559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular dental visual aids
Description: Regular dental visual aids
Study NCT01148888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
Study NCT02960152 — intervention group
Intervention type: OTHER
Intervention: diagnostic
Description: full-mouth periodontal examination
Study NCT02017418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zeaxanthin
Description: softgel
Study NCT02017418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: combinatory supplement
Description: softgel
Study NCT02697487 — intervention group
Intervention type: OTHER
Intervention: No treatment
Description: This is an observational study with no intervention.
Study NCT01982565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOx dressing
Description: The NOx dressing should be changed at least every 2 days.
Study NCT01982565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
Study NCT00827528 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional correction of anterior vaginal wall prolapse
Description: Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery.
Study NCT00827528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biologic Graft (SIS)
Description: Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery.
Study NCT00875979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg
Description: Trastuzumab emtansine was provided as a single-use lyophilized formulation.
Study NCT00875979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg
Description: Trastuzumab emtansine was provided as a single-use lyophilized formulation.
Study NCT00875979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab 420 mg
Description: Pertuzumab was provided as a single-use formulation.
Study NCT01068834 — intervention group
Intervention type: GENETIC
Intervention: KIF6 genetic test
Description: KIF6 carrier status with interpretation sheet provided to subject
Study NCT01845142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single administration of 100.000 I.U. vitamin D
Study NCT01845142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02016001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: toothpaste 1 with maximum fluoride concentration
Description: tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
Study NCT02016001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: toothpaste 2 with 1000 ppm of fluoride
Description: tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
Study NCT03802695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OrcaGraft (Orca-Q)
Description: engineered donor allograft
Study NCT01865097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation guided imagery
Description: An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
Study NCT01865097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing music
Description: An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
Study NCT01248208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist intranasal influenza vaccine
Description: FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.
Study NCT01248208 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular influenza injection (flu shot)
Description: Subjects \< 2 years or > 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.~Age 6-36 months: 0.25 mL IM x 1; Age >36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose.
Study NCT00705926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly Active Antiretroviral Therapy (HAART)
Description: Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
Study NCT00705926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No treatment
Description: Participants in this group will not receive treatment at this stage of their infection.
Study NCT03656770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.
Study NCT03795519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-olinciguat
Description: oral capsule
Study NCT03170986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisectoral agriculture and Microfinance Intervention
Study NCT03441269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ibuprofen
Description: Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
Study NCT01332331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan - low dose
Description: body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
Study NCT01332331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan - high dose
Description: body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
Study NCT01342276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vHFC
Description: Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
Study NCT04671524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: a combination of stretching, range of motion, and strengthening exercise.
Study NCT03120234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT03120234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT03120234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT03120234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: o.9% normal saline will be used instead of ketamine
Study NCT01464996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive: OptiBond XTR; Composite: Herculite Ultra
Description: The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.
Study NCT01464996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive: OptiBond FL; Composite: Herculite Ultra
Description: Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
Study NCT01118871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir, Ritonavir, Truvada
Description: Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily
Study NCT01118871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir, Ritonavir and Etravirine
Description: Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily
Study NCT01934244 — intervention group
Intervention type: DEVICE
Intervention: NovaSure Endometrial Ablation
Description: The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
Study NCT03096483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OEC Elite system
Description: Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
Study NCT00369707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
Study NCT00369707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
Study NCT03971123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin formulated as AC-SD-03 50g of AC-SD-03 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
Study NCT04233892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD-bFGF
Description: CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound
Study NCT04233892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen/BMMNCs
Description: A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound
Study NCT04233892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: Patients will receive regular estrogen therapy
Study NCT01381679 — intervention group
Intervention type: DRUG
Intervention: Ezetimibe
Description: Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
Study NCT00105066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850mg tablet once a day for one month, then twice a day for 3 months
Study NCT00105066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet once a day for one month, then twice a day for 3 months
Study NCT02048540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
Study NCT02048540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel oxaliplatin 5-FU CF
Description: docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
Study NCT02048540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel oxaliplatin 5-FU CF
Description: docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
Study NCT03971123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin formulated as AC-LMP-01 50g of AC-LMP-01 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
Study NCT02048540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy
Study NCT02048540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy